Tag: Motif-Neurotech

2 articles

Market Moves

MintNeuro raises $5 million to supply purpose-built chips to neural device makers

MintNeuro, a London semiconductor company spun out of Imperial College London, announced a $5 million round on 7 October 2026 led by Odyssey Ventures, with 33East, JSK Investments and Alumni Ventures joining and Empirical Ventures, Jumpspace Ventures and other early investors investing again. It designs modular chips for neural sensing, signal processing and stimulation that device makers can build on in place of adapted general-purpose components or years of custom chip design. Its partners include Motif Neurotech, which announced a multi-year chip supply agreement with MintNeuro on 30 April for its depression implant, and Amber Therapeutics, whose co-founder Tim Denison chairs MintNeuro. The money will fund product launches, delivery of pre-release chips to partners, a larger team and a stronger US presence. MintNeuro's last disclosed equity round was £1 million in November 2024.

Oct 8

Market Moves

The BCI category is broadening beyond motor restoration in 2026

Across the first half of 2026 and the first weeks of the second half, three US Food and Drug Administration Breakthrough Device Designations were granted to non-motor-indication BCI and neuromodulation devices, Cortigent's existing Breakthrough-designated visual cortical prosthesis programme disclosed a secondary stroke motor rehab arm, three first-in-human or investigational-device clinical milestones landed, and two significant peer-reviewed publications extended the field's clinical use case. The motor-restoration pipeline itself continued to expand in the same window. This is a synthesis piece on what the data pattern actually shows and does not show.

Jul 13